UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Reduction of Hippocampal Hyperactivity Improves Cognition in Amnestic Mild Cognitive Impairment

Neuron (Cambridge, Mass.), 2012-05, Vol.74 (3), p.467-474

2012

Volltextzugriff (PDF)

Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial

Lancet neurology, 2020-01, Vol.19 (1), p.38-48

2020

Volltextzugriff (PDF)

Seizure Rescue Therapies: Comparing Approved and Commonly Used Benzodiazepine Formulations

Neurotherapeutics, 2023-04, Vol.20 (3), p.758-766

2023

Volltextzugriff (PDF)

Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures

Neurology, 2020-06, Vol.94 (22), p.e2311

2020

Volltextzugriff (PDF)

Evaluation of adjunctive perampanel in patients with refractory partial‐onset seizures: Results of randomized global phase III study 305

Epilepsia (Copenhagen), 2013-01, Vol.54 (1), p.117-125

2013

Volltextzugriff (PDF)

Suicidality Risk of Newer Antiseizure Medications: A Meta-analysis

JAMA neurology, 2021-09, Vol.78 (9), p.1118

2021

Volltextzugriff (PDF)

Potential Influence of FDA-Sponsored Studies of Antiepilepsy Drugs on Generic and Brand-name Formulation Prescribing

JAMA neurology, 2017-08, Vol.74 (8), p.900

Krauss, Gregory L.

2017

Volltextzugriff (PDF)

Long-term Efficacy and Safety From an Open-Label Extension of Adjunctive Cenobamate in Patients With Uncontrolled Focal Seizures

Neurology, 2022-09, Vol.99 (10), p.e989

2022

Volltextzugriff (PDF)

Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open‐label safety study

Epilepsia (Copenhagen), 2020-06, Vol.61 (6), p.1099-1108

2020

Volltextzugriff (PDF)

Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial

Neurology, 2015-09, Vol.85 (11), p.950-957

2015

Volltextzugriff (PDF)

Sublingual lorazepam as rescue therapy for seizure emergencies in adults

Epilepsy & behavior, 2023-08, Vol.145, p.109294-109294, Article 109294

2023

Volltextzugriff (PDF)

Failure to use new breakthrough treatments for epilepsy

Epilepsia (Copenhagen), 2023-06, Vol.64 (6), p.1458-1465

2023

Volltextzugriff (PDF)

Normal Variants Are Commonly Overread as Interictal Epileptiform Abnormalities

Journal of clinical neurophysiology, 2019-07, Vol.36 (4), p.257-263

2019

Volltextzugriff (PDF)

Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open‐label extension of phase III randomized trials: Study 307

Epilepsia (Copenhagen), 2018-04, Vol.59 (4), p.866-876

2018

Volltextzugriff (PDF)

Non-EEG seizure detection is here

Neurology, 2018-01, Vol.90 (5), p.207-208

2018

Volltextzugriff (PDF)

Association Between Midlife Risk Factors and Late-Onset Epilepsy: Results From the Atherosclerosis Risk in Communities Study

JAMA neurology, 2018-11, Vol.75 (11), p.1375

2018

Volltextzugriff (PDF)

Long‐term safety of adjunctive cenobamate in patients with uncontrolled focal seizures: Open‐label extension of a randomized clinical study

Epilepsia (Copenhagen), 2021-09, Vol.62 (9), p.2142-2150

2021

Volltextzugriff (PDF)

Long‐term safety of perampanel and seizure outcomes in refractory partial‐onset seizures and secondarily generalized seizures: Results from phase III extension study 307

Epilepsia (Copenhagen), 2014-07, Vol.55 (7), p.1058-1068

2014

Volltextzugriff (PDF)

MRI and EEG accurately classify favorable prognosis for patients with postanoxic myoclonus: Paradigm shift

Neurology, 2020-07, Vol.95 (4), p.149-150

2020

Volltextzugriff (PDF)

Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304

Neurology, 2012-08, Vol.79 (6), p.589-596

2012

Volltextzugriff (PDF)

Cenobamate treatment of focal-onset seizures: Quality of life and outcome during up to eight years of treatment

Epilepsy & behavior, 2021-03, Vol.116, p.107796-107796, Article 107796

2021

Volltextzugriff (PDF)

Dementia in late-onset epilepsy: The Atherosclerosis Risk in Communities study

Neurology, 2020-12, Vol.95 (24), p.e3248

2020

Volltextzugriff (PDF)

Efficacy of cenobamate for uncontrolled focal seizures in patients with previous epilepsy-related surgery: Post hoc analysis of a phase 3, multicenter, open-label study

Epilepsy research, 2022-08, Vol.184, p.106952-106952, Article 106952

2022

Volltextzugriff (PDF)

Response of the medial temporal lobe network in amnestic mild cognitive impairment to therapeutic intervention assessed by fMRI and memory task performance

NeuroImage clinical, 2015-01, Vol.7 (C), p.688-698

2015

Volltextzugriff (PDF)

Cognitive and psychiatric adverse events during adjunctive cenobamate treatment in phase 2 and phase 3 clinical studies

Epilepsy & behavior, 2024-02, Vol.151, p.109605-109605, Article 109605

2024

Volltextzugriff (PDF)

1 – 25 von 335

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(311)
Mit Volltextzugriff
(221)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(335)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Neurology
(65)
Epilepsia
(38)
Epilepsy & Behavior
(20)
Epilepsy Currents
(16)
Annals Of Neurology
(15)
Epiliepsy Currents/epilepsy Currents
(9)
Electroencephalography And Clinical Neurophysiology
(8)
Jama Neurology
(7)
Archives Of Neurology
(6)
Estuaries And Coasts
(5)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Reduction of Hippocampal Hyperactivity Improves Cognition in Amnestic Mild Cognitive Impairment

Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial

Seizure Rescue Therapies: Comparing Approved and Commonly Used Benzodiazepine Formulations

Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures

Evaluation of adjunctive perampanel in patients with refractory partial‐onset seizures: Results of randomized global phase III study 305

Suicidality Risk of Newer Antiseizure Medications: A Meta-analysis

Potential Influence of FDA-Sponsored Studies of Antiepilepsy Drugs on Generic and Brand-name Formulation Prescribing

Long-term Efficacy and Safety From an Open-Label Extension of Adjunctive Cenobamate in Patients With Uncontrolled Focal Seizures

Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open‐label safety study

Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial

Sublingual lorazepam as rescue therapy for seizure emergencies in adults

Failure to use new breakthrough treatments for epilepsy

Normal Variants Are Commonly Overread as Interictal Epileptiform Abnormalities

Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open‐label extension of phase III randomized trials: Study 307

Non-EEG seizure detection is here

Association Between Midlife Risk Factors and Late-Onset Epilepsy: Results From the Atherosclerosis Risk in Communities Study

Long‐term safety of adjunctive cenobamate in patients with uncontrolled focal seizures: Open‐label extension of a randomized clinical study

Long‐term safety of perampanel and seizure outcomes in refractory partial‐onset seizures and secondarily generalized seizures: Results from phase III extension study 307

MRI and EEG accurately classify favorable prognosis for patients with postanoxic myoclonus: Paradigm shift

Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304

Cenobamate treatment of focal-onset seizures: Quality of life and outcome during up to eight years of treatment

Dementia in late-onset epilepsy: The Atherosclerosis Risk in Communities study

Efficacy of cenobamate for uncontrolled focal seizures in patients with previous epilepsy-related surgery: Post hoc analysis of a phase 3, multicenter, open-label study

Response of the medial temporal lobe network in amnestic mild cognitive impairment to therapeutic intervention assessed by fMRI and memory task performance

Cognitive and psychiatric adverse events during adjunctive cenobamate treatment in phase 2 and phase 3 clinical studies

Suchergebnisse filtern